Literature DB >> 32253501

Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review.

Takanori Ichikawa1, Yasuhiro Shimojima2, Dai Kishida1, Tomoki Kaneko3, Yoshiki Sekijima1.   

Abstract

Primary central nervous system lymphoma (PCNSL) sometimes occurs in immune-compromised hosts or patients with autoimmune diseases. Some cohort studies have previously reported an increased risk of non-Hodgkin's lymphoma in systemic lupus erythematosus (SLE), while some cases of PCNSL in patients with SLE were reported. We present the case of PCNSL which developed in a patient with the active phase of neuropsychiatric SLE (NPSLE). Furthermore, we reviewed published English articles to confirm the characteristics of PCNSL related to SLE. To our knowledge, this is the first report of PCNSL occurring in NPSLE. Histology demonstrated B-cell lymphoma with a positive Epstein-Barr virus-encoded RNA. This patient recovered following surgical resection of the lymphoma, whole brain radiation therapy, intravenous infusion of rituximab (RTX), and administration of belimumab after RTX. Given the series of reviews, our report suggests that the persistence of damage in the central nervous system (CNS) and long-term exposure to immunosuppressants may impact oncogenic immune responses within the CNS, leading to PCNSL development.

Entities:  

Keywords:  Epstein–Barr virus; Immunosuppressant; Neuropsychiatric systemic lupus erythematosus; Primary central nervous system lymphoma; Systemic lupus erythematosus

Year:  2020        PMID: 32253501     DOI: 10.1007/s00296-020-04569-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  48 in total

Review 1.  Primary lymphoma of the central nervous system--a diagnostic challenge.

Authors:  Martina Deckert; Anna Brunn; Manuel Montesinos-Rongen; Maria Rosa Terreni; Maurilio Ponzoni
Journal:  Hematol Oncol       Date:  2013-08-16       Impact factor: 5.271

Review 2.  Diagnosis and management of primary central nervous system lymphoma.

Authors:  Catherine H Han; Tracy T Batchelor
Journal:  Cancer       Date:  2017-09-26       Impact factor: 6.860

3.  Cancer risk in systemic lupus: an updated international multi-centre cohort study.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Jeremy Labrecque; Lawrence Joseph; Jean-Francois Boivin; Michelle Petri; Asad Zoma; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Steven Edworthy; Soren Jacobsen; Caroline Gordon; Mary Anne Dooley; Christine A Peschken; John G Hanly; Graciela S Alarcón; Ola Nived; Guillermo Ruiz-Irastorza; David Isenberg; Anisur Rahman; Torsten Witte; Cynthia Aranow; Diane L Kamen; Kristjan Steinsson; Anca Askanase; Susan Barr; Lindsey A Criswell; Gunnar Sturfelt; Neha M Patel; Jean-Luc Senécal; Michel Zummer; Janet E Pope; Stephanie Ensworth; Hani El-Gabalawy; Timothy McCarthy; Lene Dreyer; John Sibley; Yvan St Pierre; Ann E Clarke
Journal:  J Autoimmun       Date:  2013-02-12       Impact factor: 7.094

4.  Development of malignant cerebral lymphoma in a patient with systemic lupus erythematosus treated with immunosuppression.

Authors:  E A Lipsmeyer
Journal:  Arthritis Rheum       Date:  1972 Mar-Apr

5.  Primary lymphoma of Meckel's cave mimicking trigeminal schwannoma: case report.

Authors:  K M Abdel Aziz; H R van Loveren
Journal:  Neurosurgery       Date:  1999-04       Impact factor: 4.654

6.  Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis.

Authors:  N Dasgupta; A C Gelber; F Racke; D M Fine
Journal:  Lupus       Date:  2005       Impact factor: 2.911

Review 7.  The risk of lymphoma development in autoimmune diseases: a meta-analysis.

Authors:  Elias Zintzaras; Michael Voulgarelis; Haralampos M Moutsopoulos
Journal:  Arch Intern Med       Date:  2005-11-14

8.  Systemic lupus erythematosus and primary cerebral lymphoma.

Authors:  A S Woolf; G Conway
Journal:  Postgrad Med J       Date:  1987-07       Impact factor: 2.401

9.  Lymphoma risk in systemic lupus: effects of disease activity versus treatment.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Lawrence Joseph; Jean-Francois Boivin; Karen H Costenbader; Murray B Urowitz; Dafna D Gladman; Paul R Fortin; Ola Nived; Michelle A Petri; Soren Jacobsen; Susan Manzi; Ellen M Ginzler; David Isenberg; Anisur Rahman; Caroline Gordon; Guillermo Ruiz-Irastorza; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Christine A Peschken; Mary Anne Dooley; Steven M Edworthy; Cynthia Aranow; Diane L Kamen; Juanita Romero-Diaz; Anca Askanase; Torsten Witte; Susan G Barr; Lindsey A Criswell; Gunnar K Sturfelt; Irene Blanco; Candace H Feldman; Lene Dreyer; Neha M Patel; Yvan St Pierre; Ann E Clarke
Journal:  Ann Rheum Dis       Date:  2013-01-08       Impact factor: 19.103

10.  Systemic lupus erythematous and malignancy risk: a meta-analysis.

Authors:  Lihong Cao; Hongyan Tong; Gaixiang Xu; Ping Liu; Haitao Meng; Jinghan Wang; Xiaoying Zhao; Yongmin Tang; Jie Jin
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.